Effect of Fluticasone Furoate and Vilanterol on Exacerbations of Chronic Obstructive Pulmonary Disease in Patients with Moderate Airflow Obstruction
暂无分享,去创建一个
F. Martinez | P. Calverley | D. Niewoehner | R. Brook | B. Celli | J. Vestbo | J. Yates | D. Newby | C. Crim | M. Dransfield | Julie A. Anderson | S. Kilbride | N. Cowans
[1] James R. Brown,et al. Lung microbiome dynamics in COPD exacerbations , 2016, European Respiratory Journal.
[2] G. Waterer,et al. Inhaled corticosteroids and the increased risk of pneumonia: what’s new? A 2015 updated review , 2016, Therapeutic advances in respiratory disease.
[3] I. Pavord,et al. Exacerbations of COPD , 2016, International journal of chronic obstructive pulmonary disease.
[4] J. Wedzicha,et al. Influence of season on exacerbation characteristics in patients with COPD. , 2012, Chest.
[5] F. Martinez,et al. The Study to Understand Mortality and Morbidity in COPD (SUMMIT) study protocol , 2012, European Respiratory Journal.
[6] A. Anzueto,et al. Number needed to treat in COPD: exacerbations versus pneumonias , 2013, Thorax.
[7] T. Lasserson,et al. Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease. , 2012, The Cochrane database of systematic reviews.
[8] T. Seemungal,et al. Reported pneumonia in patients with COPD: findings from the INSPIRE study. , 2011, Chest.
[9] C. Jenkins,et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study , 2009, Respiratory research.
[10] K. Rabe,et al. Seasonal distribution of COPD exacerbations in the Prevention of Exacerbations with Tiotropium in COPD trial. , 2013, Chest.
[11] G. Criner,et al. Prevention of acute exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline. , 2015, Chest.
[12] F. Martinez,et al. Current concepts in targeting chronic obstructive pulmonary disease pharmacotherapy: making progress towards personalised management , 2015, The Lancet.
[13] F. Martinez,et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. , 2007, American journal of respiratory and critical care medicine.
[14] N. Anthonisen,et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. , 1987, Annals of internal medicine.
[15] L. Irving,et al. A hypothesis to phenotype COPD exacerbations by aetiology , 2011, Respirology.
[16] P. Poole,et al. Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease. , 2013, The Cochrane database of systematic reviews.
[17] J. Wedzicha,et al. Upper respiratory symptoms worsen over time and relate to clinical phenotype in chronic obstructive pulmonary disease. , 2015, Annals of the American Thoracic Society.
[18] P. Calverley,et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study , 2011, European Respiratory Journal.
[19] J L Hankinson,et al. Spirometric reference values from a sample of the general U.S. population. , 1999, American journal of respiratory and critical care medicine.
[20] F. Martinez,et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial , 2016, The Lancet.
[21] F. Martinez,et al. Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD. , 2015, Annals of the American Thoracic Society.
[22] J. Wedzicha,et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. , 2010, The New England journal of medicine.
[23] T. Lasserson,et al. Combined corticosteroid and long-acting beta-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease. , 2007, The Cochrane database of systematic reviews.
[24] J. Wedzicha,et al. Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. , 2016, The New England journal of medicine.
[25] R. Sansores,et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease , 2003, European Respiratory Journal.
[26] Bartolome Celli,et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. , 2007, The New England journal of medicine.
[27] P. Calverley,et al. Maintenance therapy with budesonide and formoterol in chronicobstructive pulmonary disease , 2003, European Respiratory Journal.
[28] D. Halpin. Evaluating the effectiveness of combination therapy to prevent COPD exacerbations: the value of NNT analysis , 2005, International journal of clinical practice.
[29] T. Seemungal,et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. , 2008, American journal of respiratory and critical care medicine.
[30] G. Criner,et al. Executive summary: prevention of acute exacerbation of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline. , 2015, Chest.
[31] A. Agustí,et al. Heterogeneity of chronic obstructive pulmonary disease exacerbations: a two-axes classification proposal. , 2015, The Lancet. Respiratory medicine.
[32] X. Ou,et al. [Exacerbation phenotyping in chronic obstructive pulmonary disease]. , 2014, Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases.
[33] J. Maurer. Acute Exacerbations of Chronic Obstructive Pulmonary Disease: Identification of Biologic Clusters and Their Biomarkers , 2012 .
[34] Richard E. Isaacson,et al. The Lung Microbiome in Moderate and Severe Chronic Obstructive Pulmonary Disease , 2012, PloS one.
[35] I. Pavord,et al. Blood eosinophils and inhaled corticosteroid/long-acting β-2 agonist efficacy in COPD , 2015, Thorax.